Pulmonx Corporation
Last updated September 27, 2026
Organization details
- Legal name
- Pulmonx Corporation
- Ownership
- Public
- Status
- Active
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Redwood City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LUNG
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001127537
Board of directors
-
Alissa Hsu Lynch · DirectorSince 2023
-
Dana G. Mead Jr. · DirectorSince 2023
-
Daniel P. Florin · DirectorSince 2023
-
Georgia Melenikiotou · DirectorSince 2023
-
Glendon E. French III · Director · President and CEOSince 2023
-
Richard Ferrari · DirectorSince 2023
-
Steven S. Williamson · Director · PRESIDENT AND CEOSince 2024
-
Thomas William Burns · DirectorSince 2023
-
Tiffany Sullivan · DirectorSince 2023
Chief executives
Steven S. Williamson
· PRESIDENT AND CEO
Since March 2024
Glendon E. French III
· President and CEO
Until March 2024
· Former
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.9%
-
94.9%
-
95.4%
Board connections
6 of this board's directors also sit on 7 other boards.
- via Dana G. Mead Jr. and Georgia Melenikiotou
- via Glendon E. French III
- via Thomas William Burns
- via Richard Ferrari
- via Dana G. Mead Jr.
- via Richard Ferrari
- via Alissa Hsu Lynch
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $547,892
- 55 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | Glendon E. French III Director, Officer (President and CEO) | Open-market sale | −4,098 | $2.26 | $9,261 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −3,807 | $2.26 | $8,604 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −2,213 | $2.26 | $5,001 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −2,643 | $2.26 | $5,973 |
| Sep 1, 2026 | Glendon E. French III Director, Officer (President and CEO) | Open-market sale | −37,784 | $2.26 | $85,392 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −2,224 | $2.26 | $5,026 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −2,390 | $2.26 | $5,401 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −2,121 | $2.26 | $4,793 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −3,476 | $2.26 | $7,856 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −1,530 | $2.26 | $3,458 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −3,618 | $2.26 | $8,177 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −4,827 | $2.26 | $10,909 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −1,746 | $2.26 | $3,946 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −5,863 | $2.26 | $13,250 |
| Jun 5, 2026 | Thomas William Burns Director | Grant or award | +40,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.